{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:57:14Z","timestamp":1759334234354,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.lungcan.2021.09.018","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T03:42:52Z","timestamp":1632714172000},"page":"197-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prognostic value of CYFRA 21.1 in malignant mesothelioma: A brief report of the randomized phase II trial NVALT19"],"prefix":"10.1016","volume":"161","author":[{"given":"Cornedine J.","family":"de Gooijer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobus A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2021.09.018_b0005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2021.09.018_b0010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial","volume":"9","author":"de Gooijer","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"52","key":"10.1016\/j.lungcan.2021.09.018_b0015","doi-asserted-by":"crossref","first-page":"e5748-e","DOI":"10.1097\/MD.0000000000005748","article-title":"CYFRA 21\u20131 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study","volume":"95","author":"Zhao","year":"2016","journal-title":"Medicine"},{"issue":"8","key":"10.1016\/j.lungcan.2021.09.018_b0020","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2013.158","article-title":"Cytokeratin 19-fragments (CYFRA 21\u20131) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer","volume":"108","author":"Boeck","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2021.09.018_b0025","unstructured":"C.J. de Gooijer, V. van der Noort, M. Disselhorst, J. Quispel-Janssen, L. Schunselaar, P. Baas, D. van den Broek, M. Stuiver, A. Scherpereel, D. Fennell, J. Creaney, A. Nowak, J.A. Burgers, MS07.07: Optimizing Survival Prediction in Malignant Mesothelioma; Development and External Validation of A Clinical Prediction Model (MESOPRO). 15th International Mesothelioma Interest Group Meeting 2021 (iMig 2021) 2021."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:59:25Z","timestamp":1759237165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221005547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":5,"alternative-id":["S0169500221005547"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.09.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"type":"print","value":"0169-5002"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of CYFRA 21.1 in malignant mesothelioma: A brief report of the randomized phase II trial NVALT19","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}